Business Transformation
The Missing Middle of Pharma Personalisation
Pharma has spent years trying to personalise content The bigger opportunity may be learning before personalising
From Volume to Value
The Structural Shift Reshaping Pharma
The pharmaceutical industry is in the middle of a genuine structural transition with a fundamental rethinking of where value
Navigating the U.S. CDMO Industry
Emerging Realities and Strategic Considerations
The postpandemic belief that CDMOs would retain lasting pricing power has faded The discussion at a major healthcare
US Biosimilar Market Current Trends & Challenges
The Biologics Price Competition and Innovation Act BPCIA enacted on March was created to set up
Resilient by Design
GxP Compliance and Supply Chain Innovation in the Post-Pandemic Era
The COVID pandemic served as a powerful stress test for the pharmaceutical industry It disrupted manufacturing lines
Rethinking Evidence Strategy in HEOR Budget Planning
Health economics and outcomes research HEOR can no longer be approached as a oneanddone cookiecutter process
Driving Biotech Innovation
Navigating Fast-to-Clinic and Fast-to-Market Strategies from Discovery to Commercialization
In the dynamic landscape of pharmaceutical research small to mediumsized biotech firms many of which operate virtually
A Ǫuick start Guide for Successful Cloud Migration of Global Pharmacovigilance (GPV) IT Applications
In the everevolving regulatory landscape of Global Pharmacovigilance GPV
